NCT06360458

Methylprednisolone Adjunctive to Endovascular Treatment for Stroke

Name: Clinical Trial NCT06360458
Creator: Wan-Jin Chen
Keywords: Acute Ischemic Stroke, Methylprednisolone, Phase 3, drug, clinical trial

Methylprednisolone in Adjunctive to Endovascular Treatment for Patients With Acute Ischemic Strokes With Established Large Infarct: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Wan-Jin Chen·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Acute Ischemic Stroke
Drug/Device/Intervention: Methylprednisolone
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Wan-Jin Chen
Funder: First Affiliated Hospital of Fujian Medical University

Timeline & enrollment

Phase: Phase 3
Start date: May 01, 2024
End date: Mar 01, 2028
Enrollment: 735 participants

Primary outcome

Mortality at 90 days

Summary

The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large infarct cores (ASPECTS score 6) due to anterior circulation large vessel occlusion have not been clearly established. This is a multi-center, randomized, double-blind, placebo-controlled trial to investigate early combination therapy with methylprednisolone for reperfusion in acute large core infarction.

ICD-10 classifications

Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06360458
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06360458 through Pure Global AI's free database. This Phase 3 trial is sponsored by Wan-Jin Chen and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 735 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.